NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
CompletedN/A
Sponsor: Sanofi
Conditions: Rheumatoid Arthritis, Psoriatic Arthritis
Interventions: Leflunomide
Countries: France
The main objective of this post-authorization safety study is to assess healthcare professionals' awareness, knowledge, and behavior related to receipt and reading of the Direct Healthcare Professional Communication and educational materials for ARAVA® (leflunomide) and of the additional risk minimization measures.
Eligibility overview
Sex: ALL
Healthy volunteers: Yes
Study type: OBSERVATIONAL
Eligibility criteria
Inclusion Criteria: * Healthcare professionals working only in Saudi Arabia * For Prescribers: Orthopedics, Internists, Family Physicians, General Practitioners, Dermatologists, Obstetricians/Gynecologists, Immunologists, and Rheumatologists who prescribed leflunomide to women of childbearing potential in the six months preceding the time of the inclusion * For Prescribers: Physicians or pharmacists who have prescribed or dispensed leflunomide in a pre-specified period of the 6 months leading up to survey completion * For Pharmacists: Pharmacists (including clinical pharmacists) who have dispensed leflunomide to women of childbearing potential in the six months preceding the time of the inclusion Exclusion Criteria: * Healthcare professionals who may have conflicts of interest with the survey (i.e., employed by regulatory bodies or pharmaceutical companies) * Healthcare professionals (with a relative) involved in leflunomide -related lawsuits or associations for victims of leflunomide syndrome * Healthcare professionals who are not prescribing leflunomide * Healthcare professionals who have prescribed or dispensed leflunomide earlier than 6 months before the survey completion The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Locations (1)
- Chilly-Mazarin, France